Discordance in Histopathologic Evaluation of Melanoma Sentinel Lymph Node Biopsy with Clinical Follow-Up: Results from a Prospectively Collected Database

Dandekar, Monisha; Lowe, Lori; Fullen, Douglas R.; Johnson, Timothy M.; Sabel, Michael S.; Wong, Sandra L.; Patel, Rajiv M.

doi:10.1245/s10434-014-3773-8

Cited by 8 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 However, many patients with a good prognosis (early stage) still experience metastases, and clinicopathologic staging features are subject to variations in interobserver interpretation and reporting, [5][6][7] discordance that affects melanoma staging and ultimately patient management decisions. [8][9][10][11] With increasing cancer care costs, tools for improved risk prediction that more precisely guide resources toward high-risk patients are critical. 12 The 31-gene expression profile test has been previously reported.…”

Section: Introductionmentioning

confidence: 99%

Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients

Greenhaw

Covington²,

Kurley³

et al. 2020

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients

Greenhaw

Covington²,

Kurley³

et al. 2020

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…MSLT-I concluded that although 30 initial cases may yield a high rate of SLNB accuracy, 25 additional cases further increases SLNB proficiency . Misdiagnosis rates approaching 10% also occur in the absence of expertise in the histopathologic interpretation of SLNB for melanoma …”

Section: Resultsmentioning

confidence: 99%

Contemporary Management of Early-Stage Melanoma

Rosko

VanKoevering

McLean

et al. 2017

JAMA Facial Plast Surg

Self Cite

View full text Add to dashboard Cite

he incidence of cutaneous melanoma has increased rapidly over the past 30 years. While melanoma only accounts for 1% of skin cancers, it is responsible for the majority of skin cancer deaths. 1 It is estimated that 76 380 new cases of invasive melanoma and 68 480 new cases of melanoma in situ will be diagnosed in 2016. 1 The lifetime risk of developing melanoma has reached 1 in 33 for men and 1 in 52 for women in 2016. 2 An estimated 10 130 Americans will die from melanoma in 2016. 2 Given the large burden of disease, there is substantial energy dedicated to melanoma research. While the most important recent advances in the treatment of melanoma have been in the management of advanced disease with targeted therapies and modulation of the immune system, this systematic review provides up-to-date data and high-level evidence to support the contemporary management of early-stage melanoma. MethodsWe performed a review of the PubMed, MEDLINE, and the Cochrane Database of Systematic Reviews databases using specific search strategies. Our primary search used the terms melanoma, melanoma in situ, lentigo maligna, and head and neck. We screened articles published between January 1, 2011, and May 1, 2016. Our ini-tial search of the 3 databases yielded 1202 articles. After excluding duplicates, there were 966 citations. We restricted articles to human data reported in the English language only, which excluded 252 articles. We focused our search on cutaneous melanoma, and thus articles on mucosal melanoma were excluded. We also focused our search on early-stage melanoma (melanoma in situ, stage I, and stage II), and thus articles only addressing advanced-stage melanomas were excluded. Additionally, we excluded opinion articles and commentaries. We selected only articles deemed to provide contemporary evidence and/or major advances in the diagnosis or treatment of early-stage melanoma of the head and neck. This yielded 41 articles, which were manually reviewed (Figure 1). A careful review of the bibliographies of selected articles generated additional references. Results Diagnosis BiopsyThe first step in managing cutaneous melanoma is establishing an accurate histopathological diagnosis. An incisional biopsy removes a portion of a lesion, whereas an excisional biopsy removes the entire clinically apparent lesion. Techniques for incisional and exci-IMPORTANCE The incidence of melanoma is increasing, with 76 380 new cases of invasive melanoma and 68 480 new cases of melanoma in situ expected in 2016.OBJECTIVE To review the contemporary management of early-stage melanoma.

show abstract

“…• Inappropriate, incomplete removal of primary melanoma, with errors in Breslow thickness, ulceration and mitoses estimation; initial wide-excision of the primary tumour that may interfere with the subsequent SLNB procedure; inadequate detection, resection and evaluation of (sentinel) lymph nodes (Dandekar et al, 2014) • Different use of diagnostic terms/histopathological criteria by pathologists (Patrawala et al, 2016); incomplete histopathological reports; and not using the most recent TNM classification (Niebling et al, 2013) • Insufficient knowledge of and experience in detection and treatment of satellite or in-transit metastasis…”

Section: Stagingmentioning

confidence: 99%

ECCO essential requirements for quality cancer care for melanoma: Defining how to organise care

Wouters

2018

European Journal of Surgical Oncology

View full text Add to dashboard Cite

Discordance in Histopathologic Evaluation of Melanoma Sentinel Lymph Node Biopsy with Clinical Follow-Up: Results from a Prospectively Collected Database

Cited by 8 publications

References 27 publications

Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients

Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients

Contemporary Management of Early-Stage Melanoma

ECCO essential requirements for quality cancer care for melanoma: Defining how to organise care

Contact Info

Product

Resources

About